The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature

Encephale

Volumn 42, Issue 2, 2016, Pages 156-164

  Costemale Lacoste, J F ^a,b   Guilloux, J P ^a,c   Gaillard, R ^d,e  

^a INSERM U1178   (France)

^b BICÊTRE HOSPITAL   (France)

^c University of Paris XI   (France)

^d CENTRE DE PSYCHIATRIE ET NEUROSCIENCES   (France)

^e CENTRE HOSPITALIER SAINTE ANNE   (France)

Author keywords

GSK 3; Ketamine; Lithium; Treatment resistant depression

Indexed keywords

BETA ARRESTIN; GLYCOGEN SYNTHASE KINASE 3BETA; KETAMINE; LITHIUM; PROTEIN KINASE B; SERINE; ANTIDEPRESSANT AGENT; ENZYME INHIBITOR; GLYCOGEN SYNTHASE KINASE 3;

ANTIDEPRESSANT ACTIVITY; ARTICLE; CELL SURVIVAL; CYTOARCHITECTURE; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HUMAN; NERVE CELL GROWTH; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROPHYSIOLOGY; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYNAPTIC TRANSMISSION; TREATMENT RESISTANT DEPRESSION; ANTAGONISTS AND INHIBITORS; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; ENZYMOLOGY; META ANALYSIS; MOOD DISORDERS;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; KETAMINE; LITHIUM; MOOD DISORDERS;

EID: 84961143297     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.encep.2016.02.003     Document Type: Article

References (81)

1. Kline NS. Clinical experience with iproniazid (marsilid). J Clin Exp Psychopathol1958; 19 (2, Suppl. 1): 72-8 [discussion 78-9].
2. Kuhn R. Treatment of depressive states with an iminodibenzyl derivative (G22355). Schweiz Med Wochenschr 1957; 87 (35-36): 1135-40.
3. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review ofsupporting evidence. Am J Psychiatry 1965; 122 (5): 509-22.
4. Feighner JP. The new generation of antidepressants. J Clin Psychiatry 1983; 44 (5Pt 2): 49-55.
5. Stahl S. 5HT1A receptors and pharmacotherapy. Is serotonin receptor down-regulation linked to the mechanism of action of antidepressant drugs?Psychopharmacol Bull 1994; 30 (1): 39-43.
6. Tanis KQ, Duman RS. Intracellular signaling pathways pave roads to recoveryfor mood disorders. Ann Med 2007; 39 (7): 531-44.
7. Duman RS, Voleti B. Signaling pathways underlying the pathophysiology andtreatment of depression: novel mechanisms for rapid-acting agents. TrendsNeurosci 2012; 35 (1): 47-56.
8. Duman RS, Aghajanian GK. Neurobiology of rapid acting antidepressants: roleof BDNF and GSK-3. Neuropsychopharmacol 2014; 39 (1): 233.
9. Sani G, Napoletano F, Forte AM, et al. The wnt pathway in mood disorders. CurrNeuropharmacol 2012; 10 (3): 239-53.
10. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery.Biochem J 2001; 359 (Pt 1): 1-16.
11. Cole AR. GSK3 as a Sensor Determining Cell Fate in the Brain. Front Mol Neurosci2012; 5: 4.
12. Jope RS, Johnson GVW. The glamour and gloom of glycogen synthase kinase-3.Trends Biochem Sci 2004; 29 (2): 95-102.
13. Cross DA, Alessi DR, Cohen P, et al. Inhibition of glycogen synthase kinase-3 byinsulin mediated by protein kinase B. Nature 1995; 378 (6559): 785-9.
14. Hughes K, Nikolakaki E, Plyte SE, et al. Modulation of the glycogen synthasekinase-3 family by tyrosine phosphorylation. EMBO J 1993; 12 (2): 803-8.
15. Zunszain PA, Horowitz MA, Cattaneo A, et al. Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mecha-nisms of its antidepressant properties. Mol Psychiatry 2013; 18 (12): 1236-41.
16. Kaidanovich-Beilin O, Woodgett JR. GSK-3: functional insights from cell biologyand animal models. Front Mol Neurosci 2011; 4: 40.
17. Saito-Diaz K, Chen TW, Wang X, et al. The way Wnt works: Components andmechanism. Growth Factors Chur Switz 2013; 31 (1): 1-31.
18. Beaulieu J-M, Marion S, Rodriguiz RM, et al. A beta-arrestin 2 signaling complexmediates lithium action on behavior. Cell 2008; 132 (1): 125-36.
19. Hoeflich KP, Luo J, Rubie EA, et al. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000; 406 (6791): 86-90.
20. Development of the Nervous System; 2012. ISBN: 978-0-12-374539-2; Else-vier [Internet]. [cité 14 mai 2014]. Disponible sur: https://www.elsevier.com/books/development-of-the-nervous-system/sanes/978-0-12-374539-2.
21. Kim YT, Hur E-M, Snider WD. Zhou F-Q. Role of GSK3 Signaling in NeuronalMorphogenesis. Front Mol Neurosci 2011; 4: 48.
22. Yoshimura T, Kawano Y, Arimura N, et al. GSK-3beta regulates phosphorylationof CRMP-2 and neuronal polarity. Cell 2005; 120 (1): 137-49.
23. Jiang H, Guo W, Liang X, et al. Both the establishment and the maintenance ofneuronal polarity require active mechanisms: critical roles of GSK-3beta andits upstream regulators. Cell 2005; 120 (1): 123-35.
24. Maurer U, Preiss F, Brauns-Schubert P, et al. GSK-3-at the crossroads of celldeath and survival. J Cell Sci 2014; 127 (Pt 7): 1369-78.
25. Watcharasit P, Bijur GN, Zmijewski JW, et al. Direct, activating interactionbetween glycogen synthase kinase-3beta and p53 after DNA damage. Proc NatlAcad Sci U S A 2002; 99 (12): 7951-5.
26. Eom T-Y, Roth KA, Jope RS. Neural precursor cells are protected from apopto-sis induced by trophic factor withdrawal or genotoxic stress by inhibitors ofglycogen synthase kinase 3. J Biol Chem 2007; 282 (31): 22856-64.
27. Chuang D-M, Chen R-W, Chalecka-Franaszek E, et al. Neuroprotective effectsof lithium in cultured cells and animal models of diseases. Bipolar Disord2002; 4 (2): 129-36.
28. Li X, Bijur GN, Jope RS. Glycogen synthase kinase-3beta, mood stabilizers, andneuroprotection. Bipolar Disord 2002; 4 (2): 137-44.
29. Alvarez-Buylla A, Lim DA. For the long run: maintaining germinal niches in theadult brain. Neuron 2004; 41 (5): 683-6.
30. Spalding KL, Bergmann O, Alkass K, et al. Dynamics of hippocampal neurogen-esis in adult humans. Cell 2013; 153 (6): 1219-27.
31. Wu Q, Li Y, Xiao B. DISC1-related signaling pathways in adult neurogenesis ofthe hippocampus. Gene 2013; 518 (2): 223-30.
32. Ying Q-L, Wray J, Nichols J, et al. The ground state of embryonic stem cell self-renewal. Nature 2008; 453 (7194): 519-23.
33. Kim W-Y, Wang X, Wu Y, et al. GSK-3 is a master regulator of neural progenitorhomeostasis. Nat Neurosci 2009; 12 (11): 1390-7.
34. Duman RS. Novel therapeutic approaches beyond the serotonin receptor. BiolPsychiatry 1998; 44 (5): 324-35.
35. Carlezon Jr WA, Duman RS, Nestler EJ. The many faces of CREB. Trends Neurosci2005; 28 (8): 436-45.
36. Mao Y, Ge X, Frank CL, et al. Disrupted in schizophrenia 1 regulates neuronalprogenitor proliferation via modulation of GSK3beta/beta-catenin signaling.Cell 2009; 136 (6): 1017-31.
37. Choquet D, Triller A. The dynamic synapse. Neuron 2013; 80 (3): 691-703.
38. Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiationin the hippocampus. Nature 1993; 361 (6407): 31-9.
39. Bradley CA, Peineau S, Taghibiglou C, et al. A pivotal role of GSK-3 in synapticplasticity. Front Mol Neurosci 2012; 5: 13.
40. Peineau S, Taghibiglou C, Bradley C, et al. LTP inhibits LTD in the hippocampusvia regulation of GSK3beta. Neuron 2007; 53 (5): 703-17.
41. O'Brien WT, Harper AD, Jové F, et al. Glycogen synthase kinase-3beta haploin-sufficiency mimics the behavioral and molecular effects of lithium. J Neurosci2004; 24 (30): 6791-8.
42. Kaidanovich-Beilin O, Milman A, Weizman A, et al. Rapid antidepressive-likeactivity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol Psychiatry 2004; 55 (8): 781-4.
43. Gould TD, Einat H, Bhat R, et al. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsy-chopharmacol 2004; 7 (4): 387-90.
44. Gould TD, Picchini AM, Einat H, et al. Targeting glycogen synthase kinase-3in the CNS: implications for the development of new treatments for mooddisorders. Curr Drug Targets 2006; 7 (11): 1399-409.
45. Polter A, Beurel E, Yang S, et al. Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mooddisturbances. Neuropsychopharmacology 2010; 35 (8): 1761-74.
46. Maes M. Depression is an inflammatory disease, but cell-mediated immuneactivation is the key component of depression. Prog NeuropsychopharmacolBiol Psychiatry 2011; 35 (3): 664-75.
47. Borowski T, Kokkinidis L, Merali Z, et al. Lipopolysaccharide, centralin vivo biogenic amine variations, and anhedonia. Neuroreport 1998; 9 (17): 3797-802.
48. Green HF, Nolan YM. GSK-3 mediates the release of IL-1κ, TNF-κ and IL-10from cortical glia. Neurochem Int 2012; 61 (5): 666-71.
49. Li X, Friedman AB, Roh M-S, et al. Anesthesia and post-mortem interval pro-foundly influence the regulatory serine phosphorylation of glycogen synthasekinase-3 in mouse brain. J Neurochem 2005; 92 (3): 701-4.
50. Karege F, Perroud N, Burkhardt S, et al. Protein levels of -catenin and activa-tion state of glycogen synthase kinase-3 in major depression. A study withpostmortem prefrontal cortex. J Affect Disord 2012; 136 (1-2): 185-8.
51. Li X, Friedman AB, Zhu W, et al. Lithium regulates glycogen synthase kinase-3beta in human peripheral blood mononuclear cells: implication in thetreatment of bipolar disorder. Biol Psychiatry 2007; 61 (2): 216-22.
52. Mendez-David I, El-Ali Z, Hen R, et al. A method for biomarker measurementsin peripheral blood mononuclear cells isolated from anxious and depressedmice:-arrestin 1 protein levels in depression and treatment. Front Pharmacol2013; 4: 124.
53. Beaulieu J-M. A role for Akt and glycogen synthase kinase-3 as integrators ofdopamine and 54. serotonin neurotransmission in mental health. J PsychiatryNeurosci JPN 2012; 37 (1): 7-16.
54. Tsai S-J, Liou Y-J, Hong C-J, et al. Glycogen synthase kinase-3beta gene is asso-ciated with antidepressant treatment response in Chinese major depressivedisorder. Pharmacogenomics J 2008; 8 (6): 384-90.
55. Inkster B, Nichols TE, Saemann PG, et al. Pathway-based approaches to imaginggenetics association studies: Wnt signaling, GSK3beta substrates and majordepression. NeuroImage 2010; 53 (3): 908-17.
56. Adli M, Hollinde DL, Stamm T, et al. Response to lithium augmen-tation in depression is associated with the glycogen synthase kinase3-beta -50 T/C single nucleotide polymorphism. Biol Psychiatry 2007; 62 (11): 1295-302.
57. Bauer M, Adli M, Ricken R, et al. Role of lithium augmentation in the manage-ment of major depressive disorder. CNS Drugs 2014; 28 (4): 331-42.
58. De Montigny C, Grunberg F, Mayer A, et al. Lithium induces rapid relief ofdepression in tricyclic antidepressant drug non-responders. Br J Psychiatry JMent Sci 1981; 138: 252-6.
59. Crossley NA, Bauer M. Acceleration and augmentation of antidepressants withlithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007; 68 (6): 935-40.
60. Januel D, Poirier M-F, D'alche-Biree F, et al. Multicenter double-blind random-ized parallel-group clinical trial of efficacy of the combination clomipramine (150 mg/day) plus lithium carbonate (750 mg/day) versus clomipramine (150 mg/day) plus placebo in the treatment of unipolar major depression. JAffect Disord 2003; 76 (1-3): 191-200.
61. Bauer M, Adli M, Bschor T, et al. Lithium's emerging role in the treatment ofrefractory major depressive episodes: augmentation of antidepressants. Neu-ropsychobiology 2010; 62 (1): 36-42.
62. Bauer M, Pfennig A, Severus E, et al. World Federation of Societies of BiologicalPsychiatry (WFSBP) guidelines for biological treatment of unipolar depressivedisorders, part 1: update 2013 on the acute and continuation treatment ofunipolar depressive disorders. World J Biol Psychiatry 2013; 14 (5): 334-85.
63. NICE. CG90 Depression in adults: NICE guidance; 2010 [Internet]. [cité 15 mai2014]. Disponible sur: http://publications.nice.org.uk/depression-in-adults-cg90.
64. Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood andAnxiety Treatments (CANMAT) clinical guidelines for the management ofmajor depressive disorder in adults. III. Pharmacotherapy. J Affect Disord2009; 117 (Suppl. 1): S26-43.
65. Chang C-M, Sato S, Han C. Evidence for the benefits of nonantipsychoticpharmacological augmentation in the treatment of depression. CNS Drugs2013; 27 (Suppl. 1): S21-7.
66. Stein G, Bernadt M. Lithium augmentation therapy in tricyclic-resistant depres-sion. A controlled trial using lithium in low and normal doses. Br J Psychiatry JMent Sci 1993; 162: 634-40.
67. Edwards SJ, Hamilton V, Nherera L, et al. Lithium or an atypical antipsychoticdrug in the management of treatment-resistant depression: a system-atic review and economic evaluation. Health Technol Assess Winch Engl2013; 17 (54): 1-190.
68. Beaulieu J-M, Caron MG. Looking at lithium: molecular moods and complexbehaviour. Mol Interv 2008; 8 (5): 230-41.
69. Chalecka-Franaszek E, Chuang DM. Lithium activates the serine/threoninekinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activityin neurons. Proc Natl Acad Sci U S A 1999; 96 (15): 8745-50.
70. Golan M, Schreiber G, Avissar S. Antidepressants, beta-arrestins and GRKs: fromregulation of signal desensitization to intracellular multifunctional adaptorfunctions. Curr Pharm Des 2009; 15 (14): 1699-708.
71. Scheid MP, Woodgett JR. PKB/AKT: functional insights from genetic models.Nat Rev Mol Cell Biol 2001; 2 (10): 760-8.
72. Stephens L, Anderson K, Stokoe D, et al. Protein kinase B kinases that medi-ate phosphatidylinositol 3, 4, 5-trisphosphate-dependent activation of proteinkinase. B Science 1998; 279 (5351): 710-4.
73. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine indepressed patients. Biol Psychiatry 2000; 47 (4): 351-4.
74. Zarate Jr CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch GenPsychiatry 2006; 63 (8): 856-64.
75. Aan Het Rot M, Zarate Jr CA, Charney DS, et al. Ketamine for depression: wheredo we go from here? Biol Psychiatry 2012; 72 (7): 537-47.
76. De Maricourt P, Jay T, Goncalvès P, et al. Ketamine's antidepressant effect: literature review on clinical use. Encéphale 2014; 40 (1): 15-23.
77. De Maricourt P, Jay T, Goncalvès P, et al. Ketamine's antidepressant effect: focuson ketamine mechanisms of action. Encéphale 2014; 40 (1): 48-55.
78. Dwyer JM, Duman RS. Activation of mammalian target of rapamycin and synap-togenesis: role in the actions of rapid-acting antidepressants. Biol Psychiatry2013; 73 (12): 1189-98.
79. Li N, Lee B, Liu R-J, et al. mTOR-dependent synapse formation underl-ies the rapid antidepressant effects of NMDA antagonists. Science2010; 329 (5994): 959-64.
80. Monteggia LM, Gideons E, Kavalali ET. The role of eukaryotic elongationfactor 2 kinase in rapid antidepressant action of ketamine. Biol Psychiatry2013; 73 (12): 1199-203.
81. Duman RS. Neurobiology of stress, depression, and rapid acting antide-pressants: remodeling synaptic connections. Depress Anxiety 2014; 31 (4): 291-6.